Back to search

Article

New Mechanisms to Fund Independent Clinical Trials for Repurposing Off-Patent or Generic Medicines

2020-06-16

Abstract excerpt

<title>Abstract</title> <p>Finding new therapeutic uses for approved, off-patent or generic medicines could lead to safe, affordable and timely new treatment options for patients with high medical needs. However, due to a lack of economic incentives, pharmaceutical developers are rarely interested to invest in this type of research. Consequently, potential new uses for off-patent or generic medicines are mainly s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
93899477-3d00-588d-b07c-7340741c6b6c
DOI
10.21203/rs.3.rs-26065/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
New Mechanisms to Fund Independent Clinical Trials for Repurposing Off-Patent or Generic MedicinesDOI 10.21203/rs.3.rs-26065/v1
Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity
U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity
Impact of Investigator Initiated Trials and Industry Sponsored Trials on Medical Practice (Impact): Results of a Cohort StudySemantic proximity
Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in BrazilSemantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity
Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity
The Role of Intellectual Property Rights on Access to Medicines in the WHO African Region: 25 Years After the TRIPS AgreementSemantic proximity
Financial Feasibility Study and policy recommendations of Incremental Modified Drugs Development by the Domestic Pharmaceutical IndustrySemantic proximity
Design and rationale for an empirical investigation of the resource use and costs of investigator-initiated randomized trials in Switzerland, the United Kingdom, and GermanySemantic proximity
Towards better preclinical research: Key takeaways from confirmatory multi-laboratory trials and stakeholder discussionsSemantic proximity
Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity
Select a neighboring publication to make it the new centre.